Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma

Cirmtuzumab may enhance the therapeutic activity of ibrutinib by inhibiting ROR1-dependent signaling pathway in patients with chronic lymphocytic leukemia (CLL). Mantle cell lymphoma (MCL) is B-cell malignancy that also expresses ROR1. In this study, we found that the plasma of patients with MCL had...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jian, Chen, Yun, Chen, Liguang, Zhang, Ling, Rassenti, Laura Z., Widhopf, George F., Kipps, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973864/
https://www.ncbi.nlm.nih.gov/pubmed/29872501
http://dx.doi.org/10.18632/oncotarget.25340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973864/
https://www.ncbi.nlm.nih.gov/pubmed/29872501
http://dx.doi.org/10.18632/oncotarget.25340

Ejemplares similares